NCT02630823View on ClinicalTrials.gov

MK-3475 Immunotherapy in Endometrial Carcinoma

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

February 5, 2016

Primary Completion Date

January 1, 2019

Study Completion Date

October 3, 2020

Conditions
Endometrial CancerEndometrial CarcinomaNeoplasms, Endometrial
Interventions
DRUG

MK-3475

PROCEDURE

Surgical resection (standard of care)

DRUG

Paclitaxel (standard of care)

DRUG

Carboplatin (standard of care)

RADIATION

Radiation (standard of care)

PROCEDURE

Endometrial biopsy

PROCEDURE

Peripheral blood draw

Trial Locations (1)

63110

Washington University School of Medicine, St Louis

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Washington University School of Medicine

OTHER

NCT02630823 - MK-3475 Immunotherapy in Endometrial Carcinoma | Biotech Hunter | Biotech Hunter